Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 4/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | TACR3 | P29371 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1906909 | 0.90 | AKT1 (0.42) | TNK2PTGS2TACR3CHEK1AURKA | |
| SCHEMBL14118834 | 0.90 | PDE2A (0.39) | TNK2PTGS2TACR3CHEK1AURKA | |
| SCHEMBL1903764 | 0.90 | EGFR (0.37) | TNK2PTGS2TACR3CHEK1AURKA | |
| SCHEMBL1901360 | 0.90 | EGFR (0.36) | TNK2PTGS2TACR3CHEK1AURKA | |
| SCHEMBL14118856 | 0.89 | TNK2 (0.41) | TNK2CHEK1AURKAALDH1A1HPGD | |
| SCHEMBL1903076 | 0.86 | ALDH1A1 (0.46) | TNK2AURKAALDH1A1HPGDHSD17B10 | |
| SCHEMBL1901161 | 0.86 | AURKA (0.36) | TNK2PTGS2CHEK1AURKAKDR | |
| SCHEMBL1902848 | 0.85 | TACR3 (0.37) | TNK2PTGS2TACR3CHEK1AURKA | |
| SCHEMBL1905401 | 0.85 | TACR3 (0.36) | TNK2TACR3CHEK1AURKAKDR | |
| SCHEMBL1902637 | 0.83 | TNK2 (0.37) | TNK2PTGS2TACR3CHEK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | TNK2 33/4885PTGS2 2547/4885TACR3 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.